North America Continuous Glucose Monitoring Market

North America Continuous Glucose Monitoring Market Size

The North America continuous glucose monitoring market size was estimated at USD 5.1 billion in 2024. The market is expected to grow from USD 5.9 billion in 2025 to USD 22.6 billion in 2034, growing at a CAGR of 16.1%, according to the latest report published by Global Market Insights Inc.

The North America continuous glucose monitoring (CGM) market is experiencing steady growth, driven by several key factors. These include the high prevalence of diabetes in North America, rapid technological advancements in CGM devices, increased awareness through government initiatives and public health campaigns, and a growing preference for home-based monitoring solutions.

Continuous glucose monitoring involves the use of wearable sensor systems that track glucose levels in real time, offering a more effective way to manage diabetes. These systems typically consist of sensors, transmitters, and receivers that provide continuous data and alerts. Leading companies in the CGM market include Abbott Laboratories, Dexcom, Medtronic, F. Hoffmann-La Roche, and Senseonics.

These players focus on innovation, offering advanced systems with features such as real-time continuous glucose tracking, wearable or implantable sensors, mobile app integration, and data-sharing capabilities for both patients and healthcare providers. The emphasis is on improving accuracy, convenience, and long-term health outcomes through continuous, minimally invasive monitoring.

The market grew from USD 3.5 billion in 2021 to USD 4.5 billion in 2023. This growth has been driven by increased awareness through government initiatives and public health campaigns and a growing preference for home-based monitoring. With rising demand for personalized and convenient healthcare, CGM devices are becoming a preferred solution for diabetes management at home. These devices offer real-time access to glucose levels, reduce the need for frequent clinic visits, and empower users to self-manage their condition. Innovations such as smartphone connectivity and cloud-based data sharing are enhancing the accessibility and usability of remote monitoring, further accelerating market adoption.

The increasing prevalence of diabetes in North America is a major factor fueling market growth. For instance, according to the American Diabetes Association, approximately 38.4 million people in the U.S., representing 11.6% of the population, were living with diabetes in 2021. Of these, around 2 million had type 1 diabetes, including 304,000 children and adolescents. This growing burden has led to heightened demand for advanced diagnostic technologies, such as CGM, for effective monitoring. Thus, healthcare providers and industry leaders are intensifying their efforts and investments to address this critical public health challenge.

In addition to diabetes prevalence, rising obesity rates and lifestyle-related health issues are significantly influencing CGM adoption across North America. For instance, the Centers for Disease Control and Prevention (CDC) reported that more than 2 in 5 U.S. adults have obesity, a chronic condition closely linked to diabetes. These demographic shifts are driving increased utilization of CGM devices as part of chronic disease management strategies, particularly for conditions stemming from lifestyle-related health risks.

Continuous glucose monitoring (CGM) is a medical technology used to track glucose levels in the body continuously throughout the day and night. Unlike traditional blood glucose monitoring, which requires fingerstick blood samples, CGM systems use a small sensor inserted under the skin to measure interstitial glucose levels in real time.

North America Continuous Glucose Monitoring Market Trends

• Technological advancements in CGM devices are driving rapid market growth across North America. Innovations such as improved sensor accuracy, smaller device sizes, better wearability, and mobile app integration have significantly boosted patient adoption. These features enhance convenience and reliability, making CGMs increasingly mainstream in diabetes care.
  
• Modern CGMs provide real-time glucose tracking with up to 1,000 readings daily and require no calibration for up to 14 days. This reduces the need for fingerstick tests and improves user comfort. Devices such as Abbott’s FreeStyle Libre 3 offer minute-by-minute data, a compact design, and extended sensor life.
  
• Additionally, smartphone and insulin pump integration enables seamless data sharing and automated insulin delivery, forming the foundation of artificial pancreas systems. Medtronic’s MiniMed 780G uses predictive algorithms to dynamically adjust insulin doses. This results in better glycemic control and fewer hypoglycemic events, revolutionizing diabetes management.
  
• Furthermore, advanced CGMs now utilize AI analytics and enhanced signal processing to deliver accurate, personalized glucose insights. Their integration with broader health platforms enables proactive, hyper-personalized diabetes care. These innovations are transforming CGMs into essential tools within digital health, which is estimated to reach USD 2.19 trillion by 2034, ecosystems.
  

North America Continuous Glucose Monitoring Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

The North America continuous glucose monitoring market was valued at USD 3.5 billion in 2021. The market size reached USD 5.1 billion in 2024, from USD 3.9 billion in 2022.

Based on the component, the market is segmented into transmitters, sensors, receivers. The sensor segment led this market in 2024, accounting for the highest market share because of its non-invasive nature and extended wear duration. This segment was valued at USD 2.6 billion in 2024 and is projected to reach USD 11.6 billion by 2034, growing at a CAGR of 16.3%. This growth is due to the shift toward home-based care and personalized treatment.

In comparison, the transmitter segment, valued at USD 2.3 billion in 2024, is expected to grow to USD 10 billion by 2034, with a slightly higher CAGR of 16%, supported by wireless data transmission and cloud connectivity.

• CGM sensors are small, wearable devices that measure glucose levels in the interstitial fluid beneath the skin. Typically placed on the abdomen or upper arm, they provide continuous, real-time data. This helps users monitor glucose trends and make timely health decisions. Their compact design ensures discreet and comfortable wear.
  
• Sensors are the most widely adopted component of CGM systems due to their non-invasive nature and long-term usability. They reduce the need for frequent fingerstick tests and support better glycemic control. Many sensors now integrate with digital health platforms for seamless data access. Their user-friendly design enhances daily diabetes management.
  
• Innovations in sensor technology are expanding beyond traditional glucose monitoring. Developments in implantable sensors, AI-driven analytics, and multi-analyte detection are reshaping the market. These advancements support broader health tracking capabilities. Thus, accelerating the growth of the market.
  

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the North America continuous glucose monitoring market is segmented into hospitals, home care settings, diagnostic centres and clinics, other end users. In 2024, home care settings held the largest share of 80.9%.

• Home care settings involve the use of CGM devices by individuals within their own homes, outside clinical environments. These systems enable real-time glucose tracking and independent diabetes management. Users can share data remotely with healthcare providers. This supports personalized and convenient care.
  
• The home care segment is leading in North America due to rising demand for remote and user-friendly health solutions. Technological advancements have improved CGM device accuracy, comfort, and usability. These factors encourage wider adoption among patients. The shift reflects a growing preference for self-managed care.
  
• Additionally, patients increasingly seek tools that reduce clinic visits and offer continuous health insights. CGM devices meet this need by providing real-time data, alerts, and glucose trends at home. This empowers users to make informed decisions. Convenience and autonomy are key drivers of this trend.
  
• The rising prevalence of chronic conditions such as diabetes, combined with progress in digital health, has made home-based monitoring more scalable. This has significantly boosted the CGM market. Enhanced accessibility and integration with health platforms support long-term growth. Home care is becoming central to modern diabetes management.
  

Looking for region specific data?

Download Free PDF

The U.S. dominated the North America continuous glucose monitoring market with a market share of 96.2% in 2024. The market is driven by rising incidence of diabetes, advancements in continuous glucose monitoring technologies and a growing government initiative and campaigns.

• The U.S. continuous glucose monitoring market was valued at 3.4 billion and USD 3.7 billion in 2021 and 2022, respectively. In 2024 the market size reached USD 4.9 billion from USD 4.3 billion in 2023. 
  
• The increasing number of diabetes cases among adults and children in the U.S. is significantly driving market growth.
  
• For example, the National Institute of Health reported that in 2021, approximately 352,000 diabetes cases were diagnosed in children and adolescents under the age of 20, including 304,000 cases of type 1 diabetes.
  
• This rise in cases is contributing to the strong expansion of the U.S. market, supported by growing public awareness, favorable healthcare policies, and the increasing adoption of home-based and pediatric-friendly technologies. Continuous advancements in sensor accuracy, device connectivity, and long-term wearability are establishing continuous glucose monitoring (CGM) systems as a critical component of diabetes management across all age groups.
  

Canada continuous glucose monitoring market accounted for USD 194.7 million in 2024 and is anticipated to show lucrative growth over the forecast period.

• The rising prevalence of obesity and lifestyle-related health issues is expected to further drive market growth.
  
• For instance, according to Statista, in 2023, approximately 35.5% of Canadian adults were classified as overweight, while 30% were obese. Obesity rates in Canada have steadily increased in recent years, making it one of the country’s most significant health challenges. Being overweight or obese increases the risk of developing several serious health conditions, including diabetes.
  
• Additionally, advancements in AI-driven analytics and remote monitoring are enhancing personalized care, particularly in home settings. These innovations are helping CGM systems become a mainstream solution for diabetes management across Canada.
  

North America Continuous Glucose Monitoring Market Share

• The top five players, Abbott Laboratories, Dexcom, Medtronic, F. Hoffmann-La Roche, and Senseonics, collectively hold 99.9% of the market share in the North American continuous glucose monitoring industry. These companies continue to strengthen their market positions through technological innovation, regulatory compliance, and strategic partnerships. They are investing heavily in next-generation CGM systems that offer enhanced accuracy, longer wear times, and seamless integration with digital health platforms, supporting both clinical and home-based diabetes management.
  
• Medtronic is advancing CGM technology with its Guardian 4 sensor, which integrates with insulin pump to deliver closed-loop therapy. The company is focusing on predictive algorithms and smart dosing features to improve glycemic control and reduce hypoglycemic events, especially in pediatric and high-risk populations.
  
• Manufacturers are successfully launching real-time continuous glucose monitoring (CGM) systems that provide minute by minute glucose monitoring, order predictive alerts, and cloud data sharing. The goal of the manufacturers is to eliminate complications and provide better glycemic control by proactively making decisions and monitoring patients across all populations.
  
• Leading companies are also adopting value-based care models and expanding access through over-the-counter CGM devices, especially for non-insulin-dependent type 2 diabetes patients. These innovations are supported by mobile apps, AI-powered analytics, and personalized dashboards that enhance user engagement and simplify diabetes management in outpatient and decentralized care settings.
  

North America Continuous Glucose Monitoring Market Companies

Few of the prominent players operating in the North America continuous glucose monitoring industry include:

• Abbott Laboratories
• A. Menarini Diagnostics
• Dexcom
• F. Hoffmann-La Roche
• Glucovation
• Insulet Corporation
• i-SENS
• Medtronic
• Nemaura Medical
• Senseonics
• Sinocare
  

• Abbott Laboratories

Abbott Laboratories holds a leading position in the North America CGM market, driven by its flagship FreeStyle Libre product line. The company continues to expand its reach through innovations in sensor accuracy, affordability, and integration with digital health platforms.

F. Hoffmann-La Roche

Roch leverages its extensive global presence to strengthen market reach, operating in over 100 countries with a robust distribution network. Its CGM product portfolio includes standalone CGM systems as well as integrated solutions such as the Accu-Chek SmartGuide CGM, enhancing user experience and clinical outcomes.

• Medtronic

Medtronic is committed to research and development, continuously advancing its CGM technology. Its focus on innovation has led to, enhancing user experience and clinical outcomes such as CGM devices paired with automated insulin pump systems, offering comprehensive diabetes management.

North America Continuous Glucose Monitoring Industry News:

• In July 2024, Roche announced the CE Mark approval for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution. This approval expanded the company’s reputation in the market.
  
• In September 2024, Senseonics Holdings, Inc. announced the U.S. Food and Drug Administration (FDA) approval for its next-generation Eversense 365 CGM system, world’s first One Year CGM system. This approval is expected to increase the company’s customer base and its competitiveness in the market.
  

The North America continuous glucose monitoring market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 to 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Component

• Transmitters
• Sensors
• Receivers

Market, By End Use

• Hospitals
• Home care setting
• Diagnostic centres and clinics
• Other end use

The above information is provided for the following countries:

• U.S.
• Canada